Your US supply chain may already be deciding whether Europe is possible.
There is no US equivalent to a Qualified Person
In the US, release runs through a QA function. In the EU, a named individual must personally certify each batch before it can be used in a clinical trial. It’s a different release model, not extra paperwork.
What late discovery costs
A US biotech runs Phase 1 domestically. 18 months later, a partner wants EU sites for Phase 2. The technical agreement never addressed QP access, the CDMO has no EU-certified facility, and stability data wasn’t scoped for EU conditions. None of it was a mistake at the time. Together, it’s a 6–9 month delay.
- 6–9 months lost when EU readiness is discovered late
- 6–12 months for comparability when manufacturing moves to a second, EU-capable site
Questions to ask now
- EU capacity: Does your CDMO have EU GMP-certified capacity, or a credible path to it?
- QP provisions: Do your agreements allow for QP documentation and site access?
- Stability design: Can you add climate zone conditions without restarting the study?
- Labeling: Is there room for additional country requirements?
You don’t need to build EU infrastructure now. You just need to avoid closing the door.
How Syner-G helps
Syner-G’s integrated CMC360 model brings regulatory, quality, and CMC expertise together so your US IND decisions preserve global options, without overbuilding for markets you don’t have yet.
Plan for Europe before Europe plans for you. Connect with our team.
